Talimogene Laherparepvec
Imlygic is a prescription medication used to treat melanoma (a type of skin cancer) that cannot be removed by surgery. It is an oncolytic immunotherapy, meaning it uses a genetically modified herpes virus to attack cancer cells and stimulate an immune response against the tumor. This treatment is injected directly into melanoma lesions on the skin or in lymph nodes.
Imlygic is an injectable oncolytic virus therapy used to treat inoperable melanoma by directly attacking tumors and triggering an immune response against cancer cells.
Key facts at a glance
- RxNorm
- 1721279
- Generic
- Imlygic
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Imlygic is indicated for the treatment of unresectable (cannot be surgically removed) recurrent melanoma in patients who have also received prior systemic therapy. It is injected directly into visible or palpable melanoma lesions in the skin or lymph nodes.
Imlygic is a genetically modified herpes simplex virus type 1 (HSV-1) that selectively replicates within tumors, causing tumor cell death. The virus also produces a protein (GM-CSF) that stimulates the patient's immune system to recognize and attack cancer cells, potentially affecting both treated and untreated lesions.
Imlygic is contraindicated in immunocompromised patients and pregnant women due to the risk of disseminated herpes infection. Common side effects include fatigue, chills, fever, nausea, and injection site reactions. Healthcare providers should use appropriate precautions when handling and administering this medication to avoid transmission to close contacts.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy